Patients must not have clinical evidence of central nervous system involvement by lymphoma; if performed, any laboratory or radiographic tests performed to assess central nervous system (CNS) involvement must be negative
Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization
Known central nervous system (CNS) involvement
Patients with a known central nervous system (CNS) involvement of lymphoma are not eligible (CNS staging not required)
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Current or past history of central nervous system (CNS) disease, or CNS involvement by MM
Central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement of lymphoma are not eligible
Evidence of leukemic meningitis or other central nervous system (CNS) involvement by leukemia
Patients must not have known central nervous system (CNS) involvement of lymphoma
Has clinical signs of central nervous system (CNS) involvement of MM.
Known central nervous system (CNS) involvement by lymphoma
Central nervous system (CNS) involvement by lymphoma/leukemia
Known central nervous system (CNS) involvement by malignancy
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Known central nervous system (CNS) involvement with CLL or T-LGL
Prior central nervous system (CNS) involvement by tumor cells;
Known central nervous system (CNS) involvement
Patients with history of central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
The toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknown
Known central nervous system (CNS) involvement by lymphoma
Central nervous system (CNS) involvement, including lymphomatous meningitis
Prior central nervous system (CNS) involvement by tumor cells
Participant has known Central Nervous System (CNS) involvement with AML.
History of plasma cell leukemia or multiple myeloma (MM) central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Central nervous system (CNS) involvement
Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months
Central nervous system (CNS) involvement by lymphoma
Central nervous system (CNS) involvement
Central nervous system (CNS) involvement by lymphoma (clinically or cytologically confirmed)
Patients with known central nervous system (CNS) involvement
Known brain metastases or central nervous system (CNS) involvement
Known central nervous system (CNS) tumor involvement
History of plasma cell leukemia or MM central nervous system (CNS) involvement
Central nervous system (CNS) involvement
Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment
Central nervous system (CNS) involvement within 3 months
Patient must have no current or prior history of central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Patients with known central nervous system (CNS) involvement by leukemia
History of plasma cell leukemia or central nervous system (CNS) involvement
Known central nervous system (CNS) involvement with lymphoma.
Patient has distant metastatic disease, including central nervous system (CNS) tumor involvement
Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:
Symptomatic central nervous system (CNS) involvement by AML
Untreated central nervous system (CNS) involvement
Uncontrolled central nervous system (CNS) disease involvement
AML central nervous system (CNS) involvement
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy
Patients must have no known central nervous system (CNS) involvement by lymphoma
Central nervous system (CNS) involvement by lymphoma/leukemia
Patients who have symptomatic central nervous system (CNS) involvement are not eligible
Central nervous system (CNS) involvement.
Patients with documented central nervous system (CNS) involvement
Patient must have no known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by malignancy
Known central nervous system (CNS) involvement
Symptomatic central nervous system (CNS) lymphoma involvement
Subjects with known or suspected central nervous system (CNS) involvement are not eligible
Patients with known central nervous system (CNS) involvement are excluded from this clinical trial
Central nervous system (CNS) involvement by CLL.
Research participants with known brain metastases (central nervous system [CNS] involvement either parenchymal or leptomeningeal involvement)
Has evidence of uncontrolled central nervous system (CNS) involvement (previous radiation and off steroids is acceptable)
Central nervous system (CNS) involvement by lymphoma
Phase II: Patients with untreated, relapsed or refractory T-cell lymphoma, including patients with central nervous system (CNS) involvement or lymphomatous meningitis are allowed on study
History of central nervous system (CNS) involvement by myeloma
Known central nervous system (CNS) involvement of lymphoma
Known central nervous system (CNS) involvement
Central nervous system (CNS) involvement of the patient's lymphoma
Patients with central nervous system (CNS) involvement refractory to intrathecal chemotherapy and/or standard cranial-spinal radiation
Patients with central nervous system (CNS) involvement
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by lymphoma.
Uncontrolled central nervous system (CNS) involvement with disease
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Known central nervous system (CNS) lymphoma involvement
Evidence of AML central nervous system (CNS) involvement
Central nervous system (CNS) involvement.
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy and/or standard cranial-spinal radiotherapy
Central nervous system (CNS) involvement with disease refractory to intrathecal chemotherapy
Patient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded.
Known central nervous system lymphoma or ALL with central nervous system (CNS) involvement
Central nervous system (CNS) involvement of DLBCL
Current central nervous system (CNS) involvement by lymphoma
Known central nervous system (CNS) involvement
Symptomatic central nervous system (CNS) involvement
Symptomatic central nervous system (CNS) involvement
Symptomatic, steroid-requiring or progressive central nervous system (CNS) involvement
Clinically uncontrolled central nervous system (CNS) involvement
Patients with central nervous system (CNS) metastatic involvement.
Clinically uncontrolled central nervous system (CNS) involvement
Patients must not have clinical evidence of central nervous system involvement by lymphoma, since proposed treatment would not be able to address it adequately; any laboratory (e.g., lactate dehydrogenase [LDH]) or radiographic tests performed to access central nervous system (CNS) involvement must be negative and must be performed within 42 days prior to registration
Known central nervous system (CNS) involvement
Known Central Nervous System (CNS) involvement by lymphoma.
Presence of central nervous system (CNS) involvement with Hodgkin lymphoma
Uncontrolled central nervous system (CNS) involvement by tumor cells
Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma
History of central nervous system (CNS) involvement
Known presence of central nervous system (CNS) involvement by lymphoma
Known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Participants with known central nervous system (CNS) involvement of lymphoma
Known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement by AML
Patients must not have known central nervous system (CNS) involvement
Patients with known central nervous system (CNS) involvement
Known central nervous system (CNS) involvement of lymphoma (CNS staging not required)
Clinical signs of central nervous system (CNS) involvement of MM.